Yulian Mytsyk1, Victor Dosenko2, Yuriy Borys3, Askold Kucher4, Katarina Gazdikova5,6, Dietrich Busselberg7, Martin Caprnda8, Peter Kruzliak9,10,11, Ammad Ahmad Farooqi12, Manyuk Lubov13. 1. Department of Urology, Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, Lviv, Ukraine. mytsyk.yulian@gmail.com. 2. Department of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine. 3. Department of Urology, Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, Lviv, Ukraine. 4. Department of Radiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. 5. Department of Nutrition, Faculty of Nursing and Professional Health Studies, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovak Republic. katarina.gazdikova@szu.sk. 6. Department of General Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic. katarina.gazdikova@szu.sk. 7. Weill Cornell Medical College in Qatar, Qatar Foundation, Education City, Doha, Qatar. 8. 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia. 9. Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic. kruzliakpeter@gmail.com. 10. Research and Development Services, Brno, Czech Republic. kruzliakpeter@gmail.com. 11. 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekarska 664/53, 656 91, Brno, Czech Republic. kruzliakpeter@gmail.com. 12. Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore, Pakistan. 13. Department of Foreign Languages, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
Abstract
INTRODUCTION: Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. MATERIALS AND METHODS: In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. RESULTS: We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. CONCLUSIONS: MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.
INTRODUCTION: Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. MATERIALS AND METHODS: In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. RESULTS: We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. CONCLUSIONS:MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.
Authors: Richard E Link; Sam B Bhayani; Mohammed E Allaf; Ioannis Varkarakis; Takeshi Inagaki; Craig Rogers; Li-Ming Su; Thomas W Jarrett; Louis R Kavoussi Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Zachary L Smith; Eugene J Pietzak; Chelsey K Meise; Keith Van Arsdalen; Alan J Wein; S Bruce Malkowicz; Thomas J Guzzo Journal: Can J Urol Date: 2015-12 Impact factor: 1.344
Authors: Yulian Mytsyk; Yuriy Borys; Lesia Tumanovska; Dmytro Stroy; Askold Kucher; Katarina Gazdikova; Luis Rodrigo; Peter Kruzliak; Robert Prosecky; Peter Urdzik; Victor Dosenko Journal: Clin Exp Med Date: 2019-08-22 Impact factor: 3.984
Authors: Patrick O Richard; Philippe D Violette; Bimal Bhindi; Rodney H Breau; Wassim Kassouf; Luke T Lavallée; Michael Jewett; John R Kachura; Anil Kapoor; Maxine Noel-Lamy; Michael Ordon; Stephen E Pautler; Frédéric Pouliot; Alan I So; Ricardo A Rendon; Simon Tanguay; Christine Collins; Maryam Kandi; Bobby Shayegan; Andrew Weller; Antonio Finelli; Andrea Kokorovic; Jay Nayak Journal: Can Urol Assoc J Date: 2022-02 Impact factor: 1.862
Authors: Melanie von Brandenstein; Stephan H Bernhart; Andreas Pansky; Claudia Richter; Tobias Kohl; Martina Deckert; Axel Heidenreich; Peter F Stadler; Manuel Montesinos-Rongen; Jochen W U Fries Journal: Oncotarget Date: 2018-08-28